Edition:
United Kingdom

Foamix Pharmaceuticals Ltd (FOMX.OQ)

FOMX.OQ on NASDAQ Stock Exchange Global Market

6.08USD
20 Feb 2018
Change (% chg)

$0.22 (+3.75%)
Prev Close
$5.86
Open
$5.88
Day's High
$6.25
Day's Low
$5.88
Volume
13,469
Avg. Vol
28,309
52-wk High
$10.29
52-wk Low
$4.03

Chart for

About

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and... (more)

Overall

Beta: --
Market Cap(Mil.): $241.40
Shares Outstanding(Mil.): 37.43
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Tamarkin Medical Reports 7.3 Percent Passive Stake In Foamix Pharmaceuticals

* TAMARKIN MEDICAL INNOVATIONS LTD REPORTS 7.3 PERCENT PASSIVE STAKE IN FOAMIX PHARMACEUTICALS AS OF DECEMBER 31, 2017 - SEC FILING Source text: (http://bit.ly/2so9g8s) Further company coverage:

13 Feb 2018

BRIEF-Foamix Announces Positive Results From Late Stage Acne Treatment Study

* FOAMIX ANNOUNCES POSITIVE RESULTS FROM PHASE 3 OPEN-LABEL SAFETY EXTENSION EVALUATING FMX-101 TOPICAL MINOCYCLINE FOAM FOR TREATMENT UP TO 1 YEAR Source text for Eikon: Further company coverage:

04 Jan 2018

BRIEF-Foamix Names David Domzalski As A Member Of Company Board

* FOAMIX NAMES MR. DAVID DOMZALSKI AS A MEMBER OF THE BOARD OF FOAMIX PHARMACEUTICALS

03 Jan 2018

BRIEF-Foamix Q3 loss per share $0.47

* Foamix reports third quarter 2017 financial results and provides business update

15 Nov 2017

Earnings vs. Estimates